Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer.
E. Van Cutsem
Research Funding - Roche; Sanofi
C. Boni
Consultant or Advisory Role - Sanofi
J. Tabernero
Consultant or Advisory Role - Roche; Sanofi
B. Massuti
Consultant or Advisory Role - Roche
D. A. Richards
No relevant relationships to disclose
H. Prenen
No relevant relationships to disclose
I. Steinberg
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
P. Rougier
Consultant or Advisory Role - Sanofi